PYGO2

Across TCGA pan-cancer cohorts, PYGO2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PYGO2 data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PYGO2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PYGO2 expression acts as an unfavorable survival marker.

BLCA, COAD, and BRCA are the cancer types where PYGO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
COAD	DFS	Median	II,III,IV	0.126	0.747	<.001	13	view →
BRCA	OS	Median	All	0.581	0.924	<.001	12	view →
READ	DFS	Median	All	0.112	0.845	.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PYGO2–BLCA (OS)

Open the BLCA breakdown →